Status:
RECRUITING
Artificial Intelligence in Mammography Screening in Norway
Lead Sponsor:
Norwegian Institute of Public Health
Collaborating Sponsors:
Helse Vest
Helse Midt-Norge
Conditions:
Breast Cancer
Eligibility:
FEMALE
50-69 years
Phase:
NA
Brief Summary
The purpose of this randomized controlled trial is to compare the number of breast cancers detected among women who had their screening mammograms interpreted by artificial intelligence (AI) in combin...
Detailed Description
Independent double reading with consensus is the recommended practice for breast cancer screening programs in Europe. This is a time-consuming process and more than 99% of examinations are determined ...
Eligibility Criteria
Inclusion
- Women attending the population-based mammography screening program BreastScreen Norway providing a signed, informed consent
Exclusion
- Women attending the population-based mammography screening program BreastScreen Norway not providing a signed, informed consent
Key Trial Info
Start Date :
November 25 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2033
Estimated Enrollment :
150000 Patients enrolled
Trial Details
Trial ID
NCT06032390
Start Date
November 25 2024
End Date
June 1 2033
Last Update
December 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cancer Registry of Norway, Norwegian Institute of Public Health
Oslo, Norway